Table 2.
Efficacy and adverse effects of treatment
| All | Sorafenib | Lenvatinib | P‐value | |
|---|---|---|---|---|
| N | 513 | 309 | 204 | |
| Duration of treatment | 111 (1–1932) | 107 (1–1932) | 115 (1–922) | NS |
| ORR | 21% | 15% | 30% | <0.001 |
| DCR | 59% | 50% | 75% | <0.001 |
| AE, total | 64% | 64% | 65% | NS |
| AE, HFS | 24% | 28% | 18% | 0.002 |
| AE, proteinuria | 7% | 4% | 12% | 0.004 |
| AE, hypertension | 16% | 14% | 18% | NS |
| AE, fatigue | 13% | 11% | 15% | NS |
| AE, appetite loss | 9% | 7% | 11% | NS |
Values are median (range) or percent of patients.
AE, adverse effect; DCR, disease control rate; HFS, hand foot syndrome; NS, not significant; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival.